Navigation Links
Shaping Best Practices For Standardized Medical Imaging In Clinical Trials
Date:8/26/2008

The Drug Information Association (DIA), in collaboration with FDA, the Medical Imaging Contrast Agent Association (MICAA), the Council on Radionuclides and Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), will host Medical Imaging Continuum: Path Forward for Advancing the Uses of Medical Imaging in the Development of New Biopharmaceutical Products (October 2-3; Bethesda, MD)

Horsham, PA (Vocus) August 26, 2008-- http://www.diahome.org/ [The Drug Information Association (DIA)], in collaboration with FDA, the Medical Imaging Contrast Agent Association (MICAA), the Council on Radionuclides and Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), will host http://www.diahome.org/ [Medical Imaging Continuum: Path Forward for Advancing the Uses of Medical Imaging in the Development of New Biopharmaceutical Products] (October 2-3; Bethesda, MD)

This workshop will provide updates on the harmonization and standardization of the key elements required to meet the FDA review process and Proposed Draft Regulatory Guidance of 2011. This effort is currently in progress with PhRMA, the Extended PhRMA Imaging Group, CORAR, MICAA and many other stakeholders who are shaping best practices for standardizing medical imaging in clinical trials, including academia, professional imaging societies, non-profit consortia, governmental agencies, and regulatory authorities.

Attendees will discuss "Metrics for Quantifying the Quality of Imaging Enterprises in Clinical Trials" and "How to Standardize Image Acquisition, Transfer, and Analysis." Potential outcomes will include:

  • Endorsement of a rigorously defined metrics that quantify the quality of imaging enterprises in biopharmaceutical development;

  • An explanation of the issues surrounding the quantification of adjudication rates across therapeutic areas and imaging technologies;

  • Harmonization of imaging as a quantitative measure of drug-induced changes in multi-center clinical trials; and

  • The adoption of a standard, open-source, internet-based application for transferring data from sites of acquisition to central repositories.
"Working alongside experts from academia, professional imaging societies, non-profit consortia, and governmental agencies, meeting attendees will help to shape best practices for standardized medical imaging in clinical trials," notes Program Chair P. David Mozley, MD, Senior Director, Imaging, Merck Research Laboratories.

About the http://www.diahome.org/ [Drug Information Association (DIA)]
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, and Mumbai, India, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Joe Krasowski
215-293-5812
Joe.Krasowski@diahome.org

###


Read the full story at http://www.prweb.com/releases/2008/08/prweb1237524.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. VOICES Launches Vote Kids 2008 to Engage Voters and Candidates in Shaping National Policies for Americas Children
2. Reshaping pharmaceutical quality
3. The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing
4. Honda Criticized for Discriminatory Insurance Practices
5. URAC Reveals Distinguished Judges Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards
6. New Research From Best Practices: Pharmaceutical New Product Planning - Structure and Activities to Drive Growth and Profitability
7. Non-parental care of infants tied to unfavorable feeding practices
8. Associated Builders & Contractors, Inc. Launches Campaign Against Discriminatory Practices of Almac and Skanska USA
9. Best Practices: Achieving Excellence in Staffing and Recruiting Methods
10. High-Performing Sales Forces Share Key Practices to Achieve Optimal Performance
11. Kingfisher Healthcare (KFH) Wins Prestigious Frost & Sullivan Best Practices Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever ... stuff. The season for grass pollen runs from May to July each year; with the ... victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against ...
(Date:3/29/2017)... ... 29, 2017 , ... Wells Pharmacy Network, a proud A4M ... upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO ... leader in the training of physicians, scientists, and members of the public on ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Dr. Angela Cotey, ... orthodontic treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey ... have a better orthodontic outcome and experience. When patients receive early treatment, they may ...
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... South Hills of Pittsburgh now have easier access to the robotic-assisted total-hip ... Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 30, 2017  Akcea Therapeutics, a subsidiary of Ionis ... a Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx ... goal of the study is to determine the dose ... in a planned Phase 3 cardiovascular outcome study. ... strategic collaboration with Novartis to develop and commercialize drugs ...
(Date:3/29/2017)... March 29, 2017  Bodycad announced today that ... (FDA) 510(k) clearance for its Bodycad Unicompartmental Knee ... personalized orthopaedic restoration. Bodycad is the first Canadian ... reconstruction implant system. Bodycad,s revolutionary ... restoration of the patient,s unique anatomical features and ...
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology: